15. Whittaker E., Bamford A., Kenny J., et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020; 324 (3): 259–69. DOI: https://doi.org/10.1001/jama.2020.10369
16. Chilazi M., Duffy E.Y., Thakkar A., et al. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021; 23 (7): 37. DOI: https://doi.org/10.1007/s11883-021-00935-2
17. Tavazzi G., Pellegrini C., Maurelli M., et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020; 22 (5): 911–5.
18. Zhou Y., Fu B., Zheng X., et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020; 7 (6): 998–1002. DOI: https://doi.org/10.1093/nsr/nwaa041
19. Kubasiak L.A., Hernandez O.M., Bishopric N.H., et al. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA. 2002; 99: 12 825–30.
20. Han H., Xie L., Liu R., et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020; 92 (7): 819–23. DOI: https://doi.org/10.1002/jmv.25809
21. Wehbe Z., Hammoud S.H., Yassine H.M., et al. Molecular and biological mechanisms underlying gender differences in COVID-19 severity and mortality. Front Immunol. 2021; 12: 659339. DOI: https://doi.org/10.3389/fimmu.2021.659339
22. Brojakowska A., Narula J., Shimony R., et al. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC Review Topic of the Week. J Am Coll Cardiol. 2020; 75 (24): 3085–95. DOI: https://doi.org/10.1016/j.jacc.2020.04.028
23. Gupta A., Madhavan M.V., Sehgal K., et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26 (7): 1017–32. DOI: https://doi.org/10.1038/s41591-020-0968-3
24. Ishyama Y., Gallagher P.E., Averill D.B., et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43: 970–6.
25. Wang K., Chen W., Zhang Z., et al. CD 147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020; 5 (1): 283. DOI: https://doi.org/10.1038/s41392-020-00426-x
26. Castiello T., Georgiopoulos G., Finocchiaro G., et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2022; 27 (1): 251–61. DOI: https://doi.org/10.1007/s10741-021-10087-9
27. Escher F., Pietsch H., Aleshcheva G., et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020; 7 (5): 2440–7.
28. Trogen B., Gonzalez F.J., Shust G.F. COVID-19-associated myocarditis in an adolescent. Pediatr Infect Dis J. 2020; 39 (8): e204–5. DOI: https://doi.org/10.1097/INF.0000000000002788
29. Cryer M.J., Farhan S., Kaufmann C.C., et al. Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized COVID-19 positive patients: a review. Clin Appl Thromb Hemost. 2022; 28: 10760296221074353. DOI: https://doi.org/10.1177/10760296221074353
30. Salamanca J., Díez-Villanueva P., Martínez P., et al. COVID-19 «fulminant myocarditis» successfully treated with temporary mechanical circulatory support. JACC Cardiovasc Imaging. 2020; 13 (11): 2457–9. DOI: https://doi.org/10.1016/j.jcmg.2020.05.003
31. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–62.
32. Caro-Codon J., Rey J.R., Buno A., et al.; CARD-COVID Investigators. Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail. 2021; 23 (3): 456–64. DOI: https://doi.org/10.1002/ejhf.2095
33. Sorrentino S., Cacia M., Leo I., et al. B-type natriuretc peptide as biomarker of COVID-19 disease severity – a meta-analysis. J Clin Med. 2020; 9: 2957.
34. Sala S., Peretto G., Gramegna M., et al. Acute myocarditis presenting as a reverse tako-tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020; 41 (19): 1861–2. DOI: https://doi.org/10.1093/eurheartj/ehaa286
35. Meyer P., Degrauwe S., Van Delden C., et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020; 41 (19): 1860. DOI: https://doi.org/10.1093/eurheartj/ehaa306
36. Kumar N.R., Patel S., Norwood B. Subacute cardiac tamponade in a COVID-19 patient despite negative testing. Cureus. 2022; 14 (9): e29090. DOI: https://doi.org/10.7759/cureus.29090
37. Tung-Chen Y. Acute pericarditis due to COVID-19 infection: an underdiagnosed disease? Med Clin (Barc). 2020; 155 (1): 44–5. DOI: https://doi.org/10.1016/j.medcli.2020.04.007
38. Miro Ò., Sabate M., Jimenez S., et al.; Spanish Investigators on Emergency Situations TeAm (SIESTA) network; SIESTA network. A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emerg Med J. 2022. DOI: https://doi.org/10.1136/emermed-2020-210977 Online ahead of print.
39. Gopinathannair R., Merchant F.M., Lakkireddy D.R., et al. COVID-19 and cardiac arrythmias: a global perspective on arrythmias characteristics and management strategies. J Interv Card Electrophysiol. 2020; 59 (2): 329–36.
40. Duckheim M., Schreieck J. COVID-19 and cardiac arrhythmias. Hamostaseologie. 2021; 41 (5): 372–8. DOI: https://doi.org/10.1055/a-1581-6881
41. Lazzerini P.E., Boutjdir M., Capecchi P.L. COVID-19, arrythmic risk, and inflammation: mind the gap! Circulation. 2020; 142 (1): 7–9.
42. Dherange P., Lang J., Qian P., et al. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020; 6 (9): 1193–204.
43. Shi S., Qin M., Shen B., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 802–10.
44. Matvienko O. Yu., Korsakova N.E., Lerner A.A., et al. Plasma hemostasis in patients with coronavirus infection caused by SARS-COV-2. Tromboz, gemostaz i reologiya [Thrombosis, Hemostasis and Rheology]. 2020; (4): 52–6. DOI: https://doi.org/10.25555/THR.2020.4.0945 (in Russian)
45. Matvienko O. Yu., Smirnova O.A., Lerner A.A., et al. Assessment of the state of the hemostasis system in patients with coronavirus infection using a thrombin generation test. Byulleten’ meditsinskoy nauki [Bulletin of Medical Science]. 2021: 2 (22): 95–8. DOI: https://doi.org/10.31684/25418475_2021_2_95 (in Russian)
46. Tam C.F., Cheung K.S., Lam S., et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020; 13 (4): e006631.
47. Basbus L., Lapidus M.I., Martingano I., et al. Neutrophil to lymphocyte ratio as a prognostic marker in COVID-19. Medicina (B Aires). 2020; 80 (suppl 3): 31–6.
48. Chopra V., Flanders S.A., O’Malley M., et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021; 174 (4): 576–8. DOI: https://doi.org/10.7326/M20-5661
49. Johansson M., Stahlberg M., Runold M., et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic Tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021; 3 (4): 573–80. DOI: https://doi.org/10.1016/j.jaccas.2021.01.009